All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Moderna's mRESVIA receives UK marketing authorization for respiratory syncytial virus prevention in adults 60+ years old
Vaccine, lower respiratory tract disease, respiratory syncytial virus (RSV) - Read more

Mitsubishi Tanabe Pharma's Reagila (dopamine D3/D2 receptor partial agonist) approved in Thailand for adjunctive therapy in major depressive disorder
Small molecule, major depressive disorder - Read more

Regeneron's linvoseltamab (targeting BCMA) recommended for EU approval to treat relapsed/refractory multiple myeloma after three prior therapies
Monoclonal antibody, cancer, multiple myeloma - Read more

Eisai and Biogen's anti-beta-amyloid antibody Leqembi remains on track for European approval for Alzheimer's disease after panel reaffirms positive opinion.
Monoclonal antibody, Alzheimer's disease - Read more

AbbVie's upadacitinib (JAK inhibitor) receives positive CHMP opinion for treating adult giant cell arteritis
Small molecule, giant cell arteritis - Read more

Vertex's Kaftrio (ivacaftor/tezacaftor/elexacaftor combination, CFTR modulator) receives positive CHMP opinion for cystic fibrosis patients aged 2+ with non-class I mutations
Small molecule, cystic fibrosis (CF) - Read more

Novartis's Fabhalta (Factor B inhibitor) receives positive CHMP opinion for treating adults with C3 glomerulopathy
Small molecule, C3 glomerulopathy - Read more

PRESENTED BY TLDR BIOTECH
What would you do with nearly 6,000 meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

⬇️ More Good News ⬇️

THE GOOD
Business Development

Nxera Pharma receives $10M from Viatris for Asia-Pacific rights to lupus clinical-stage asset cenerimod (S1P 1 receptor modulator)
Small molecule, systemic lupus erythematosus - Read more

Eisai licenses cancer drug tasurgratinib (targeting FGFR2) to SciClone Pharmaceuticals in Greater China for upfront payment, milestones, and royalties
Small molecule, biliary tract cancer - Read more

Nxera Pharma signs distribution deal with Holling to distribute daridorexant (targeting OX1R, OX2R) in Taiwan, receiving upfront payment and future royalties
Small molecule, insomnia - Read more

THE GOOD
Clinical Trials

LongBio Pharma touts positive Ph2 data for LP-003 (anti-IgE) versus omalizumab in chronic spontaneous urticaria
Monoclonal antibody, chronic spontaneous urticaria - Read more

Jasper Therapeutics touts positive Ph1b/2a data for briquilimab (anti-c-Kit) in treating chronic spontaneous urticaria
Small molecule, chronic spontaneous urticaria, chronic inducible urticaria, asthma - Read more

AstraZeneca and Amgen showcases positive Ph3 data for Tezspire (targeting TSLP) in chronic rhinosinusitis with nasal polyps, while GSK presented depemokimab data in the same indication
Monoclonal antibody, chronic rhinosinusitis with nasal polyps - Read more

Fapon Biopharma's FP008 (anti-PD-1×IL-10M) receives FDA IND approval for solid tumors refractory to anti-PD-1 therapy
Fusion protein, solid tumor, cancer- Read more

THE GOOD
Fundraises

Magnet Biomedicine received $40M from Eli Lilly equity investment as part of broader drug discovery platform partnership
Small molecule, molecular glue, platform technology, drug discovery - Read more

THE GOOD
Investments

Delaware offers Merck & Co. $30M grant to build commercial facility at Chestnut Run Innovation Park near Wilmington
Facility build - Read more

THE GOOD
IPO

BridgeBio Oncology Therapeutics going public via merger with Helix SPAC, raising $450 million from deal and investors
Small molecule, lung cancer, SPAC - Read more

THE GOOD
Mergers & Acquisition

Pacira BioSciences acquires remaining 81% stake in GQ Bio for $32 million, expanding its gene therapy capabilities
Gene therapy, knee osteoarthritis, adenovirus - Read more

THE GOOD
Partnerships

Eli Lilly, Magnet Biomedicine sign molecular glue discovery technology partnership via $1.2B+ licensing deal
Small molecule, molecular glue, platform technology, drug discovery - Read more

THE GOOD
Politics & Policy

Six major drugmakers agree to participate in second round of Medicare price negotiations
Inflation reduction act, drug pricing - Read more [Paywall]

Infectious disease experts plan independent vaccine advisory group in response to potential “eroding” of CDC committee by RFK Jr.
Vaccine policy, vaccine panel - Read more [Paywall]

THE GOOD
Regulatory

Canada's Drug Agency issues new guidelines for rare disease registries, aimed at enhancing data quality and healthcare decision-making
Rare disease guidance, regulatory guidance - Read more

THE GOOD
Research

ElevateBio's gene therapy reduced toxic protein in Huntington's mice by 80%, spurring search for development partners
Gene therapy, Huntington's disease - Read more

Research reveals Huntington's disease is caused by gene expansion triggering neuron death, not protein buildup, opening new treatment possibilities
Huntington's disease - Read more

Scientists discovered a gene variant (HAQ-STING) that protects against COPA Syndrome, potentially leading to new gene therapy treatments
Gene therapy, COPA Syndrome - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Praxis Precision Medicines barges ahead with Ph3 trial of ulixacaltamide (targeting T-type calcium channels) in essential tremor despite futility study findings
Small molecule, essential tremor - Read more

THE BAD
Earnings & Finances

Recursion Pharmaceuticals reports larger than expected Q4 loss of $0.53 per share, missing analyst estimates
Small molecule, drug discovery, AI, cancer - Read more

Syros Pharmaceuticals will voluntarily delist from Nasdaq and deregister with SEC by March 2025, ending reporting obligations.
Stock delisting, small molecule, cancer, myeloid leukemia, solid tumor - Read more

THE BAD
Layoffs

Bristol Myers Squibb laying off 223 more workers in New Jersey as part of cost-cutting plan to save $2 billion annually
Big pharma strategy, big pharma layoffs - Read more

CRISPR Therapeutics cuts jobs across multiple departments including scientists and manufacturing staff; number of layoffs undisclosed
Gene-editing, CRISPR - Read more [Paywall]

Adagio Medical cuts staff and pauses European cryoablation catheter launch to focus on US trial
Medical device, catheter ablation - Read more

THE UGLY
No ugly news today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here